20 years ago, our hyaluronic acid-based lubricant eye drops meet high compliance and patient satisfaction.
Affecting between 5% and 34% of people worldwide, Dry eye disease represents a significant economic burden due to direct and indirect healthcare costs such as reduced work productivity.1,2,3 We have developed the VISMED® (range of lubricant eye drops consisting of hypo-osmolar sodium hyaluronate solutions) to treat symptoms and signs of dry eye, ocular surface damage and eye irritation due to different diseases such as superficial keratitis, Sjögren’s syndrome, or primary dry eye syndrome.4-6 The VISMED® product range has been formulated in order to break the vicious cycle of dry eye by counteracting tear hyperosmolarity and stabilising the tear film.7 With a choice of sodium hyaluronate concentrations varying from 0.1% to 0.3%, we offer an adaptable range of concentrations to meet the patient’s specific needs.
- Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71-81.
- Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334-65.
- Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264-8.
- Vismed European instructions for use, last revision date: April 2012
- Vismed Gel European instructions for use, last revision date: September 2015
- Vismed Light European instructions for use, last revision date: September 2016
- Montes-Mico R, Caliz A, Alio JL. Changes in ocular aberrations after instillation of artificial tears in dry-eye patients. J Cataract Refract Surg. 2004;30:1649-52.